Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
|
journal
|
October 2018 |
Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
|
journal
|
December 2014 |
Synthesis and cytotoxicity of novel dispiro derivatives of 5-arylidenoxazolones, potential inhibitors of p53—MDM2 protein-protein interaction
|
journal
|
March 2018 |
Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment
|
journal
|
October 2015 |
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures
|
journal
|
December 2015 |
Early and multiple origins of metastatic lineages within primary tumors
|
journal
|
February 2016 |
The catalytic asymmetric synthesis of CF 3 -containing spiro-oxindole–pyrrolidine–pyrazolone compounds through squaramide-catalyzed 1,3-dipolar cycloaddition
|
journal
|
January 2019 |
JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells
|
journal
|
May 2017 |
Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation
|
journal
|
December 2014 |
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner
|
journal
|
April 2016 |
The chemistry and pharmacology of privileged pyrroloquinazolines
|
journal
|
January 2015 |
Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
|
journal
|
March 2017 |
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
|
journal
|
July 2017 |
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
|
journal
|
October 2016 |
Therapeutic targeting of tumor suppressor genes: Therapeutic Targeting of Tumors
|
journal
|
December 2014 |
RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
|
journal
|
November 2019 |
Organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation
|
journal
|
January 2015 |
Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
|
journal
|
January 2018 |
Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations
|
journal
|
April 2019 |
The Role of MDM2 in Promoting Genome Stability versus Instability
|
journal
|
October 2017 |
The utilization of spirocyclic scaffolds in novel drug discovery
|
journal
|
June 2016 |
Chemical Variations on the p53 Reactivation Theme
|
journal
|
May 2016 |
Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors
|
journal
|
March 2017 |
RSK3: A regulator of pathological cardiac remodeling: Regulation and Function of RSK3 in Cardiac Remodeling
|
journal
|
May 2015 |
2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008–2014)
|
journal
|
December 2015 |
A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation
|
journal
|
January 2019 |
Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
|
journal
|
December 2016 |
Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
|
journal
|
July 2018 |
Efficient Synthesis of Fully Substituted Pyrrolidine-Fused 3-Spirooxindoles via 1,3-Dipolar Cycloaddition of Aziridine and 3-Ylideneoxindole
|
journal
|
August 2016 |
The role of p53 in cancer drug resistance and targeted chemotherapy
|
journal
|
November 2016 |
A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53 wt osteosarcoma cells
|
journal
|
February 2019 |
Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
|
journal
|
April 2017 |
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
|
journal
|
December 2017 |
Targeting MDM2 for novel molecular therapy: Beyond oncology
|
journal
|
October 2019 |
A regio- and stereocontrolled approach to the synthesis of 4-CF 3 -substituted spiro[chromeno[3,4- c ]pyrrolidine-oxindoles] via reversible [3+2] cycloaddition of azomethine ylides generated from isatins and sarcosine to 3-nitro-2-(trifluoromethyl)-2 H -chromenes
|
journal
|
January 2019 |
A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53
|
journal
|
November 2017 |
Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy: ANTICANCER COMPOUNDS TARGETING CELL DEATH
|
journal
|
June 2016 |
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
|
journal
|
July 2019 |
Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction: STRATEGIES TO DISRUPT THE p53-MDM2/MDMX INTERACTION
|
journal
|
June 2016 |
Synthesis of benzosuberone-tethered spirooxindoles: 1-3-dipolar cycloaddition of azomethine ylides and arylidene benzosuberones
|
journal
|
December 2018 |
Efficient synthesis of tetrahydronaphthalene- or isochroman-fused spirooxindoles using tandem reactions
|
journal
|
January 2015 |
Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
|
journal
|
February 2015 |
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
|
journal
|
August 2017 |
Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
|
journal
|
August 2018 |
Chiral bifunctional bisphosphine enabled enantioselective tandem Michael addition of tryptamine-derived oxindoles to ynones
|
journal
|
January 2019 |
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
|
journal
|
March 2019 |
Design, synthesis and evaluations of spiro‐fused benzoxaborin derivatives as novel boron‐containing compounds
|
journal
|
March 2019 |
Targeting Transcription Factors for Cancer Treatment
|
journal
|
June 2018 |
Organocatalytic asymmetric Michael addition between 3-subsituted oxindoles and enals catalyzed by camphor sulfonyl hydrazine
|
journal
|
January 2019 |
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments
|
journal
|
May 2019 |
Targeting transcription factors in acute myeloid leukemia
|
journal
|
June 2018 |
The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53
|
journal
|
October 2019 |
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
|
journal
|
April 2016 |
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
|
journal
|
March 2017 |
Cellular Senescence: Aging, Cancer, and Injury
|
journal
|
April 2019 |
P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
|
journal
|
March 2016 |
Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
|
journal
|
November 2019 |